BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250918T190000
DTEND;TZID=Africa/Nairobi:20250918T203000
DTSTAMP:20260423T230539
CREATED:20250915T115752Z
LAST-MODIFIED:20250916T123756Z
UID:40417-1758222000-1758227400@kesho-kenya.org
SUMMARY:Management of CML Blast Crisis
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nMANAGEMENT OF CML Blast Crisis \n📅 Date: 18th September 2025⏰ Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Angela McligeyoPhysician and Medical Oncologist \nSPEAKERProfessor Gianantonio RostiIRCCS IRST “Dino Amadori”\, Meldola (Italy)Managing CML in Blast Crisis When Intensive Treatment Options are Available \nSPEAKERProfessor Malkit RiyatAssociate Professor of Haematology & Consultant Haematologist\, Aga Khan University Hospital\, NairobiManaging CML in Blast Crisis When Intensive Treatment Options are Limited \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=” Click to Register” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_dqr0xaQTQ4azL00zAgi9Aw”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cml-blast-crisis/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-16-at-11.46.45-AM-e1758026251987.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250911T190000
DTEND;TZID=Africa/Nairobi:20250911T203000
DTSTAMP:20260423T230539
CREATED:20250909T145133Z
LAST-MODIFIED:20250909T150805Z
UID:40404-1757617200-1757622600@kesho-kenya.org
SUMMARY:Palliative Support and Pain Management
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Moderator: \n\nDr. Zipporah Ali – Palliative Care Physician and Public Health Specialist\n\nSpeakers: \n\nDr. Lee Ngugi – Pain Management Specialist\, Anaesthesiologist & Lecturer\, Kenyatta University\, School of Medicine\, NairobiTopic: Interventional Pain Management Procedures in Cancer-Related Pain\nDr. Esther Munyoro – Neuro-anaesthetist & Palliative Care Specialist\, Former Head of Pain and Palliative Care Unit\, Kenyatta National Hospital\, NairobiTopic: Palliative care: Making it real\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=””][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/support-and-pain-management/
CATEGORIES:Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-09-at-1.11.19-PM-e1757429658184.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250904T190000
DTEND;TZID=Africa/Nairobi:20250904T203000
DTSTAMP:20260423T230539
CREATED:20250902T070734Z
LAST-MODIFIED:20250902T074433Z
UID:40392-1757012400-1757017800@kesho-kenya.org
SUMMARY:Paediatric Bone Marrow Transplantation
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nDate & Time:📅 4th September 2025🕖 7:00 PM – 8:30 PM (EAT) \nModerator:Dr. Robert KimutaiConsultant Paediatrician & Haematologist-Oncologist\,MP Shah Hospital\, Nairobi \nSpeaker:Dr. Brian NderuConsultant Paediatrician & Haematologist-Oncologist\,Gertrude’s Children’s Hospital\, NairobiTopic: Paediatric Bone Marrow Transplant: Immense Possibilities \n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_4YrYt-keT5yLYGrVG-811Q”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/bone-marrow-transplantation/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-02-at-9.30.03-AM-e1756796966321.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250828T190000
DTEND;TZID=Africa/Nairobi:20250828T193000
DTSTAMP:20260423T230539
CREATED:20250828T155020Z
LAST-MODIFIED:20250828T160124Z
UID:40384-1756407600-1756409400@kesho-kenya.org
SUMMARY:Cancer Care
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nModerator: \n\nDr. Anne Mwirigi – Consultant Haematologist & Assistant Professor\, Aga Khan University Hospital\, Nairobi\n\nSpeakers: \n\nDr. Arjun Ghosh – Consultant Cardiologist\, Barts Heart Centre (BHC)\, St. Bartholomew’s Hospital\, London & University College London Hospital\nDr. Manel Haj Mansour – Consultant Medical Oncologist & Section Head of Medical Oncology\, Aga Khan University Hospital\, Nairobi\nDr. Charles Kariuki – Interventional Cardiologist\, Ubora Heart\, The Nairobi Hospital\nDr. Gladwell Kiarie – Medical Oncologist\, The Nairobi Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_8tHcTBq9RQyHW5ptZ_-OdA”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-care/
CATEGORIES:CME 2023,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-28-at-7.05.53-AM-e1756396849381.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250807T190000
DTEND;TZID=Africa/Nairobi:20250807T203000
DTSTAMP:20260423T230539
CREATED:20250805T170900Z
LAST-MODIFIED:20250805T174804Z
UID:40344-1754593200-1754598600@kesho-kenya.org
SUMMARY:Cervical Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nSpeakers:\n\nDr. Dulcie Wanda\n\n\nClinical & Radiation Oncologist\nHead of Department\, Nakuru Regional Cancer Treatment Centre\n\nTopic: Radiotherapy in Management of Advanced Cancer of the Cervix. \n2. Dr. Edward Sang \n\nGynaecologist and Oncologist\, MP Shah Doctors Plaza\, Nairobi\n\nTopic: Surgical Techniques in Cervical Cancer \nModerator:\nDr. Afrin Fatima Shaffi \n\nGynecologic Oncologist\, Nairobi West Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_KINXix7MSqys9Q4p_rWZhQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cervical-cancer-3/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-05-at-4.13.55-PM-1-e1754414483969.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250731T190000
DTEND;TZID=Africa/Nairobi:20250731T203000
DTSTAMP:20260423T230539
CREATED:20250414T202143Z
LAST-MODIFIED:20250806T123353Z
UID:24416-1753988400-1753993800@kesho-kenya.org
SUMMARY:Bone Marrow Transplant
DESCRIPTION:Date: 31 July 2025 | 7:00 – 8:30PM EAT \nModerator: Dr Matilda Ongondi \nDr. Rohini Radia – Bone Marrow Transplantation  \nBone marrow transplantation (BMT) is a potentially curative treatment for various blood cancers and benign hematologic conditions like sickle cell disease and aplastic anemia. It involves high-risk procedures requiring meticulous planning and long-term follow-up. \nThere are two main types: \nAutologous (using the patient’s own cells) and Allogeneic (using donor cells). Allogeneic BMT carries a higher treatment-related mortality (10–25%) and risk of complications such as graft-versus-host disease (GVHD)\, infections\, and infertility\, but it is the only curative option for several conditions. Autologous BMT is safer (TRM <5%) and commonly used in myeloma and lymphomas. \nPatient and donor selection\, conditioning protocols\, and GVHD prophylaxis are tailored individually. Long-term follow-up is essential\, especially due to chronic GVHD and relapse risks. In sickle cell disease\, allogeneic HSCT offers a potential cure but requires careful risk-benefit consideration. \nSuccess in BMT depends on early identification\, thorough preparation\, and sustained multidisciplinary care beyond the immediate post-transplant period.
URL:https://kesho-kenya.org/event/bone-marrow-transplant/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250801-WA0000-e1754042861975.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250724T190000
DTEND;TZID=Africa/Nairobi:20250724T203000
DTSTAMP:20260423T230539
CREATED:20250414T201502Z
LAST-MODIFIED:20250806T120327Z
UID:24407-1753383600-1753389000@kesho-kenya.org
SUMMARY:Sarcoma Care
DESCRIPTION:Bridging Gaps in Soft Tissue Sarcoma Care \nDate: 24 July 2025 | 7:00 – 8:30pm EAT \nModerator: Dr Rose Munge \nDr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa\nSoft tissue sarcomas are rare malignant tumors of mesenchymal origin\, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm)\, high recurrence (78%)\, and better outcomes with radical excisions. \nChemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However\, access to radiotherapy remains limited\, impacting outcomes. Timely radiotherapy\, as seen in Tanzania\, improves survival. \nKey gaps include limited resources\, lack of local treatment guidelines\, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers\, local research\, and developing Africa-specific management guidelines.
URL:https://kesho-kenya.org/event/sarcoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Sarcoma-Care-e1754481435270.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250717T190000
DTEND;TZID=Africa/Nairobi:20250717T203000
DTSTAMP:20260423T230539
CREATED:20250414T201147Z
LAST-MODIFIED:20250806T114844Z
UID:24403-1752778800-1752784200@kesho-kenya.org
SUMMARY:Endometrial Cancer
DESCRIPTION:Moderator: Dr Anisa Mburu\n1. Dr. Caroline Tonio – Advanced Endometrial Cancer\nDr. Tonio’s presentation highlighted significant advancements in the treatment of advanced and recurrent endometrial cancer. With rising incidence and poor outcomes in late-stage disease\, treatment has evolved from conventional chemotherapy to biomarker-driven strategies. \nMolecular subtyping\, as identified by the TCGA\, has enabled the use of immune checkpoint inhibitors (ICIs) and targeted therapies. Notably\, ICIs like dostarlimab and pembrolizumab show strong efficacy in dMMR/MSI-H tumors. Emerging combinations of ICIs with chemotherapy or TKIs are improving survival outcomes. The integration of molecular profiling is now essential in selecting optimal therapies. Future care will increasingly rely on predictive biomarkers to guide personalized treatment. \n2. Dr. Khadija Warfa – Endometrial Cancer Pathology and Surgical Staging\nDr. Warfa provided an overview of the pathology\, risk factors\, and staging of endometrial cancer. Most cases occur in postmenopausal women\, with abnormal bleeding as a common symptom. Risk factors include estrogen exposure\, obesity\, and genetic syndromes. \nDiagnosis relies on biopsy and imaging. Pathologically\, cancers are divided into Type I and II\, with molecular subtypes (e.g.\, POLE\, dMMR\, p53-abn) offering greater prognostic value. \nStandard surgical management involves hysterectomy with lymph node assessment. Sentinel lymph node biopsy is preferred in many cases due to lower complication rates. Minimally invasive approaches offer comparable survival outcomes with reduced morbidity.
URL:https://kesho-kenya.org/event/endometrial-cancer-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/04/unnamed-e1752574943250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250710T190000
DTEND;TZID=Africa/Nairobi:20250710T203000
DTSTAMP:20260423T230539
CREATED:20250414T201718Z
LAST-MODIFIED:20250806T125314Z
UID:24409-1752174000-1752179400@kesho-kenya.org
SUMMARY:Prostate Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Date: 10 July 2025 | Time: 7:00 – 8:30PM EAT \nModerator: Dr Ahmed Komen \nDr Muigai Mararo – Management Algorithm for Metastatic Prostate Cancer\nDr Mararo presented a concise framework detailing oligometastatic local therapies (stereotactic radiotherapy or nodal resection)\, first‑line androgen‑deprivation therapy (continuous orchiectomy or LHRH analogue) combined with AR pathway inhibitors or docetaxel (with or without triplet combinations)\, radiotherapy for low‑volume disease\, and the sequencing of novel agents (second‑generation antiandrogens\, PARP inhibitors\, radioligand therapy) in castration‑resistant settings\, alongside essential supportive measures (bone protection\, multidisciplinary review). \nDr. Syokau Ilovi – Role of Germline Genetic Testing in Prostate Cancer\nAbout 10% of prostate cancers harbor pathogenic germline variants (notably BRCA1/2 and other HRR genes)\, prompting universal testing in metastatic disease and selective panels in high‑risk localized cases; implementation includes multigene panels\, variant classification (pathogenic\, VUS)\, genetic counseling\, cascade testing for relatives\, and periodic reclassification to inform personalized therapy and family risk management. \nDr. Mercy Gatua – Advances in Management of Metastatic Prostate Cancer: The Role of PARP Inhibitors\nPARP inhibitors exploit homologous recombination repair deficiencies (up to 30% of mCRPC\, especially BRCA2 mutations) by inducing lethal double‑strand DNA breaks; key trials (TOPARP\, PROfound\, TRITON3\, PROpel) demonstrate significant rPFS and OS benefits as monotherapy or combined with AR pathway inhibitors in germline/somatic HRR‑mutated cohorts\, supporting FDA/EMA approvals and integration into first‑line and later‑line mCRPC treatment algorithms. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/prostate-cancer-6/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-07-07-at-11.29.37-AM-e1751892629661.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250703T190000
DTEND;TZID=Africa/Nairobi:20250703T203000
DTSTAMP:20260423T230539
CREATED:20250414T201819Z
LAST-MODIFIED:20250806T125526Z
UID:24411-1751569200-1751574600@kesho-kenya.org
SUMMARY:Lymphoma Management in Africa
DESCRIPTION:Date: 3 July 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Beatrice Jepngetich \nDr. Anne Mwirigi – Relapsed/Refractory DLBCL \nDr. Anne Mwirigi presented a stage IVB germinal-center DLBCL case to illustrate why approximately 14% of Kenyan patients fail standard R-CHOP\, highlighting that true primary-refractory disease carries a median survival under nine months. She emphasized early risk stratification using IPI scoring\, interim PET imaging\, and molecular markers to identify high-risk individuals. For chemosensitive relapses\, salvage regimens such as R-GDP and R-ICE can bridge to autologous stem cell transplant; however\, CAR-T therapy and CD3×CD20 bispecific antibodies deliver the highest response rates. Practical recommendations included confirming residual disease with biopsy\, accelerating cellular therapy referral in primary-progressive cases\, and advocating for regional access programs to overcome cost barriers. \nDr. Jonathan Wawire – High-Grade B-Cell Lymphoma Entities \nDr. Jonathan Wawire decoded the WHO 5th-edition classification of high-grade B-cell lymphomas\, clarifying that a Ki-67 index ≥80% and dual MYC/BCL2 or BCL6 rearrangements define the most aggressive subtypes. He noted Kenya’s elevated prevalence of non-GCB and double-expresser lymphomas\, which correlate with poorer outcomes and necessitate intensified regimens. Key diagnostic insights included routine Ki-67 quantification\, Hans/Choi cell-of-origin algorithms\, and reflex FISH panels for precise double-hit detection. He stressed that accurate subclassification is essential for deciding when to intensify therapy beyond R-CHOP—such as DA-EPOCH-R—or to enrol patients in clinical trials\, ensuring truly personalized care for aggressive lymphoma in African settings.
URL:https://kesho-kenya.org/event/lymphoma-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-29-at-8.28.07-AM-scaled-e1751238405443.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250625T190000
DTEND;TZID=Africa/Nairobi:20250625T203000
DTSTAMP:20260423T230539
CREATED:20251223T210004Z
LAST-MODIFIED:20251223T210004Z
UID:40823-1750878000-1750883400@kesho-kenya.org
SUMMARY:Sickle Cell Disease
DESCRIPTION:
URL:https://kesho-kenya.org/event/sickle-cell-disease-3/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250619T190000
DTEND;TZID=Africa/Nairobi:20250619T203000
DTSTAMP:20260423T230539
CREATED:20250414T202032Z
LAST-MODIFIED:20250806T125949Z
UID:24414-1750359600-1750365000@kesho-kenya.org
SUMMARY:Sickle Cell Disease
DESCRIPTION:Date: 19 June 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Peter Oyiro \nProf. Jessie Githang’a – Sickle Cell Clinical Trials in Kenya \nProf. Jessie Githang’a emphasized the need for more SCD clinical trials in Africa\, where the disease burden is greatest. She outlined the underrepresentation of African populations in global trials and highlighted the benefits of local research\, including better understanding of drug efficacy\, safety\, and socio-genetic differences. She discussed ongoing and past trials in Kenya involving Hydroxyurea\, Crizanlizumab\, and gene therapies\, noting challenges like infrastructure gaps and limited expertise. Prof. Githang’a called for improved research capacity\, team collaboration\, and greater engagement with trial participants. \nDr. Doreen Mutua – Management of SCD in the 21st Century \nDr. Doreen Mutua reviewed modern SCD management\, highlighting the importance of early diagnosis\, health maintenance\, and Hydroxyurea therapy. She addressed common complications like stroke\, chronic pain\, and organ damage\, and emphasized early intervention to prevent progression. Transition of care for adolescents\, genetic counseling\, and curative options such as HSCT and gene editing were also discussed. Her presentation underscored the need for advocacy\, access to comprehensive care\, and integration of newborn screening into national systems.
URL:https://kesho-kenya.org/event/sickle-cell-disease-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-17-at-2.30.46-PM-e1750160210228.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250618T190000
DTEND;TZID=Africa/Nairobi:20250618T203000
DTSTAMP:20260423T230539
CREATED:20251223T205914Z
LAST-MODIFIED:20251223T205914Z
UID:40821-1750273200-1750278600@kesho-kenya.org
SUMMARY:Cancer and Nutrition
DESCRIPTION:
URL:https://kesho-kenya.org/event/cancer-and-nutrition/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250612T190000
DTEND;TZID=Africa/Nairobi:20250612T203000
DTSTAMP:20260423T230539
CREATED:20250414T201057Z
LAST-MODIFIED:20250806T113038Z
UID:24400-1749754800-1749760200@kesho-kenya.org
SUMMARY:Clinical Nutrition in Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr Catherine Nyongesa \nSpeakers & Topics: \n\nKennedy Okinda: Medical Nutrition Therapy Cases in Cancer Care – A Cross‑Sector Lens\nTraceyann Njeri Wacheke: Medical Nutrition Therapy in Survivorship & Secondary Cancer Prevention\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/clinical-nutrition-in-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-06-at-10.42.37-AM-scaled-e1749240060528.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250611T190000
DTEND;TZID=Africa/Nairobi:20250611T203000
DTSTAMP:20260423T230539
CREATED:20251223T205807Z
LAST-MODIFIED:20251223T205807Z
UID:40819-1749668400-1749673800@kesho-kenya.org
SUMMARY:Palliative Care: Integrative  Oncology
DESCRIPTION:
URL:https://kesho-kenya.org/event/palliative-care-integrative-oncology/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250605T190000
DTEND;TZID=Africa/Nairobi:20250605T203000
DTSTAMP:20260423T230539
CREATED:20250414T200927Z
LAST-MODIFIED:20250622T142308Z
UID:24398-1749150000-1749155400@kesho-kenya.org
SUMMARY:Cancer Survivor's Day
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof John Weru \nSpeakers & Topics: \n\nMuthoni Mate: Tokenism in Cancer Survivor Involvement – Beyond Being the Face on a Brochure\nDr Mary Nyangasi: Beyond Remission – Best Practices in Survivorship Care Planning & Patient Navigation\nDr Esther Muinga: Palliative Care as a Pillar of Survivorship\n\nMuthoni Mate highlighted the issue of tokenism where survivors are symbolically included without influence. She called for shifting from consultation to co-design and recognizing survivors as experts by experience. Obstacles include medical jargon\, lack of trauma-informed engagement\, minimal institutional support\, and preference for academic voices. True engagement must be collaborative\, compensated\, and empowering\, allowing survivors to shape policy and practice. She urged stakeholders to move beyond the ‘face on the brochure’ and include survivors meaningfully in healthcare decision-making. \nDr. Nyangasi emphasized the critical role of survivorship care planning and patient navigation in ensuring long-term quality of life for cancer survivors. She outlined survivorship as a continuum beginning at diagnosis\, extending beyond acute care into surveillance\, psychosocial support\, and lifestyle guidance. Evidence from over 60 systematic reviews shows that patient navigation improves care access\, adherence to follow-up\, and satisfaction. Barriers in Kenya include weak health systems\, low awareness\, lack of funding\, and absence of integrated care protocols. There is urgent need for structured survivorship models and investment in navigation programs with proven return on investment. \nDr. Muinga presented palliative care as integral to survivorship\, aiming to improve quality of life through pain control\, emotional support\, and end-of-life care. She emphasized the interconnectedness of palliation\, prevention\, and health promotion. Effective survivorship care requires collaboration across disciplines and includes surveillance\, psychosocial screening\, and health education. Survivorship plans should empower patients and caregivers\, incorporate national policies\, and address financial and cultural challenges. She concluded that palliative care is not about dying—it’s about living fully post-treatment.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-survivors-day/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-05-29-at-9.36.30-AM-e1748516449351.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250604T190000
DTEND;TZID=Africa/Nairobi:20250604T203000
DTSTAMP:20260423T230539
CREATED:20251223T205510Z
LAST-MODIFIED:20251223T205705Z
UID:40817-1749063600-1749069000@kesho-kenya.org
SUMMARY:Cancer Survivorship
DESCRIPTION:
URL:https://kesho-kenya.org/event/cancer-survivorship/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250528T190000
DTEND;TZID=Africa/Nairobi:20250528T203000
DTSTAMP:20260423T230539
CREATED:20251223T205348Z
LAST-MODIFIED:20251223T205348Z
UID:40815-1748458800-1748464200@kesho-kenya.org
SUMMARY:Brain Cancer / Brain Tumour
DESCRIPTION:
URL:https://kesho-kenya.org/event/brain-cancer-brain-tumour/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250524T083000
DTEND;TZID=Africa/Nairobi:20250524T160000
DTSTAMP:20260423T230539
CREATED:20250414T200830Z
LAST-MODIFIED:20250622T142308Z
UID:24396-1748075400-1748102400@kesho-kenya.org
SUMMARY:EA Oncology Summit
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]\n\n\n    Download    PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ea-oncology-summit-2/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/04/Screenshot-2025-05-20-130129-scaled-e1750167427791.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250522T190000
DTEND;TZID=Africa/Nairobi:20250522T203000
DTSTAMP:20260423T230539
CREATED:20250520T103711Z
LAST-MODIFIED:20250622T142307Z
UID:24535-1747940400-1747945800@kesho-kenya.org
SUMMARY:Multidisciplinary Approaches to Paediatric Brain Tumours
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr Alfred Odhiambo \nSpeakers & Topics: \n\nMr David L. Oluoch‑Olunya: Surgical Management of Paediatric Brain Tumours\nDr Michael Magoha: Endocrinological Management of Paediatric Brain Tumours\nDr Ahmed Korir: Radiation Therapy in Paediatric Brain Tumours\n\nMr. David Oluoch-Olunya presentation summary\n– Over 25 years\, Kenya has moved from fragmented care to growing multidisciplinary tumour boards in urban centres.\n– Key challenges remain: late diagnosis\, radiotherapy access disparities\, and poor survivorship follow-up.\n– Regional initiatives like the Brain Tumor Consortium of Africa (BTCoA) aim to standardize care and improve data sharing.\n– Priorities: expand MDT care to counties\, national paediatric tumour registry\, survivorship and rehab programs.\n– Kenya has made major strides\, but gaps persist in early detection\, diagnostics\, and referral systems. \nDr Ahmed Komen’s presentation summary \n– RT use depends on age\, tumour type/location\, other treatments\, and disease extent.\n– Modern RT techniques include 2D\, 3DCRT\, IMRT\, VMAT\, and proton therapy (where available).\n– RT aims: radical (curative) or palliative (symptom relief).\n– RT delivery to children requires precise planning and often sedation or anaesthesia.\n– Late effects of RT: cognitive decline\, growth delay\, hearing loss\, hormonal dysfunction\, secondary cancers.\n– Younger age (<7 yrs) and higher doses correlate with greater neurocognitive risks.\n– Proton therapy offers tissue-sparing benefits but has limited availability in LMICs.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/multidisciplinary-approaches-to-paediatric-brain-tumours/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/May-22nd-Poster-e1747737385167.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250515T190000
DTEND;TZID=Africa/Nairobi:20250515T203000
DTSTAMP:20260423T230539
CREATED:20250414T200633Z
LAST-MODIFIED:20250622T142308Z
UID:24390-1747335600-1747341000@kesho-kenya.org
SUMMARY:Bladder Cancer
DESCRIPTION:Moderator: Roselyne A. Okumu \nSpeakers & Topics: \n\nDr Melissa Reimers: Updates in the Management of Advanced Bladder Cancer\nProf Peter Mungai: Superficial Bladder Cancer Management\n\nManagement of Non-Muscle-Invasive Bladder Cancer (NMIBC) \n– NMIBC represents ~75% of new bladder cancer cases\, typically presenting with painless hematuria.\n– Diagnosis: Cystoscopy and TURBT; blue light cystoscopy improves detection.\n– Risk-based treatment approach:\n• Low/intermediate-risk: single post-op intravesical chemo (mitomycin C/gemcitabine)\n• High-risk: 6-week BCG induction ± maintenance\n– BCG-unresponsive NMIBC: radical cystectomy or emerging therapies.\n– Promising bladder-sparing agents: TAR-200 (gemcitabine) and TAR-210 (erdafitinib).\n– Trials (MoonRISe-3\, SunRISe-5) show >80% DFS in high-risk patients. \nUpdates in Advanced and Metastatic Bladder Cancer \n– Bladder cancer is the 4th most common male cancer globally.\n– Molecular profiling is critical: test for FGFR3 and HER2.\n– 1st-line standard: Enfortumab vedotin + Pembrolizumab (EV-302/KEYNOTE-A39).\n– Platinum-eligible: Cis/gem ± nivolumab; Carb/gem → Avelumab maintenance.\n– 2nd/3rd-line: Erdafitinib (FGFR+)\, T-DXd (HER2+).\n– Novel ADCs (Enfortumab\, Sacituzumab) offer superior outcomes to chemo.\n– Trial enrolment is encouraged for all patients. \nKey Clinical Takeaways \n– Intravesical innovation is changing NMIBC treatment beyond BCG.\n– Biomarker-driven therapy is now essential for managing advanced bladder cancer.\n– Routine molecular testing is critical for individualized care
URL:https://kesho-kenya.org/event/bladder-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Bladder-Cancer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250514T190000
DTEND;TZID=Africa/Nairobi:20250514T203000
DTSTAMP:20260423T230539
CREATED:20251223T205123Z
LAST-MODIFIED:20251223T205123Z
UID:40811-1747249200-1747254600@kesho-kenya.org
SUMMARY:Melanoma/Skin Cancer
DESCRIPTION:
URL:https://kesho-kenya.org/event/melanoma-skin-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250508T190000
DTEND;TZID=Africa/Nairobi:20250508T203000
DTSTAMP:20260423T230539
CREATED:20250414T200448Z
LAST-MODIFIED:20250622T144009Z
UID:24388-1746730800-1746736200@kesho-kenya.org
SUMMARY:Management of Indolent Lymphomas
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Nicholas Otieno Abinya \nSpeakers & Topics: \n\nDr Samson Mutanda: Practical Approaches in Clinical Case‑Driven Exploration\nProf Shahin Sayed: Histopathology & Low‑Grade Lymphomas\nDr Matilda Ongondi: CT Treatment Algorithm – A Practical Approach\n\nDr. Samson Mutanda – presented case-based exploration of CLL management in Kenyan settings.\n– Key clinical points:\n• CLL is heterogeneous and often indolent; many patients start with watchful waiting.\n• Symptomatic cytopenias and disease progression warrant treatment.\n• Therapy included bendamustine\, rituximab\, venetoclax\, and novel agents like ibrutinib.\n– Highlighted diagnostic limitations due to access to FISH\, molecular testing\, and cost of targeted therapies.\n– Underscored importance of tailored care\, especially in young patients and those with co-morbidities. \nDr. Matilda Ongondi – Provided a clinical introduction to indolent lymphomas\, which are slow-growing B-cell neoplasms such as CLL/SLL\, follicular lymphoma\, and MZL.\n– Emphasized the necessity for clinical vigilance and long-term monitoring.\n– Stressed the need for diagnostic precision\, the role of immunophenotyping\, and the heterogeneity of clinical presentations.\n– Highlighted treatment considerations: watchful waiting\, targeted therapy\, and challenges in resource-limited settings. \nProf. Shahin Sayed – Reviewed WHO-HEM5 classification of indolent lymphomas\, emphasizing pathology-driven subtypes.\n– Covered key immunophenotypic markers: CD5\, CD23\, LEF1\, BCL2\, Cyclin D1\, etc.\n– Presented rare pediatric and adolescent cases\, illustrating diagnostic complexity and variability.\n– Detailed histologic signs of aggressive transformation (e.g. high Ki-67\, prolymphocytic features).\n– Outlined molecular diagnostics: del(11q\, 13q\, 17p)\, TP53 mutations\, IGHV SHM – all important for prognosis and treatment.\n– Discussed evolving terminology: classic FL\, follicular lymphoma with uncommon features (uFL)\, and follicular large cell lymphoma.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-indolent-lymphomas/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250505-WA0000-e1746479789592.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250507T190000
DTEND;TZID=Africa/Nairobi:20250507T203000
DTSTAMP:20260423T230539
CREATED:20251223T205007Z
LAST-MODIFIED:20251223T205007Z
UID:40809-1746644400-1746649800@kesho-kenya.org
SUMMARY:Open
DESCRIPTION:
URL:https://kesho-kenya.org/event/open/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250430T190000
DTEND;TZID=Africa/Nairobi:20250430T203000
DTSTAMP:20260423T230539
CREATED:20251223T204854Z
LAST-MODIFIED:20251223T204854Z
UID:40807-1746039600-1746045000@kesho-kenya.org
SUMMARY:Testicular Cancer
DESCRIPTION:
URL:https://kesho-kenya.org/event/testicular-cancer-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250424T190000
DTEND;TZID=Africa/Nairobi:20250424T203000
DTSTAMP:20260423T230539
CREATED:20250414T200348Z
LAST-MODIFIED:20250622T144124Z
UID:24386-1745521200-1745526600@kesho-kenya.org
SUMMARY:Advanced Ovarian Cancer
DESCRIPTION:Moderator: Prof Rose J. Kosgei \nSpeakers & Topics: \n\nProf Omenge Orang’o: Management of Epithelial Ovarian Cancer\nDr Peter Oyiro: PARP Inhibitors in Ovarian Cancer\nDr Charles Muteshi: Fertility Preservation in Ovarian Cancer\n\nEpidemiology and Diagnosis (Prof. Omenge Oran’go) \n– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.\n– Kenya sees many cases diagnosed at advanced stages (III/IV)\, primarily due to non-specific symptoms and lack of screening.\n– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning. \nFertility Preservation in Ovarian Cancer (Dr. Charles Muteshi) \n– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).\n– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.\n– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential. \nRole of PARP Inhibitors (Dr. Peter Oyiro) \n– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.\n– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.\n– 7-year follow-up data show sustained benefit\, with over 48% progression-free survival in Olaparib arms.\n– Low incidence of serious adverse events\, with anemia\, fatigue\, and nausea as the most common.\n– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.
URL:https://kesho-kenya.org/event/advanced-ovarian-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250423-WA0000-e1745403823792.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250423T190000
DTEND;TZID=Africa/Nairobi:20250423T203000
DTSTAMP:20260423T230539
CREATED:20251223T204641Z
LAST-MODIFIED:20251223T204641Z
UID:40805-1745434800-1745440200@kesho-kenya.org
SUMMARY:World AML Day (21st)
DESCRIPTION:
URL:https://kesho-kenya.org/event/world-aml-day-21st/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250421T190000
DTEND;TZID=Africa/Nairobi:20250421T203000
DTSTAMP:20260423T230539
CREATED:20251223T205238Z
LAST-MODIFIED:20251223T210251Z
UID:40813-1745262000-1745267400@kesho-kenya.org
SUMMARY:Bladder Cancer
DESCRIPTION:
URL:https://kesho-kenya.org/event/bladder-cancer-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250416T190000
DTEND;TZID=Africa/Nairobi:20250416T203000
DTSTAMP:20260423T230539
CREATED:20251223T204430Z
LAST-MODIFIED:20251223T204430Z
UID:40803-1744830000-1744835400@kesho-kenya.org
SUMMARY:Head & Neck Cancer
DESCRIPTION:
URL:https://kesho-kenya.org/event/head-neck-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250410T190000
DTEND;TZID=Africa/Nairobi:20250410T203000
DTSTAMP:20260423T230539
CREATED:20250407T135020Z
LAST-MODIFIED:20250622T144124Z
UID:24249-1744311600-1744317000@kesho-kenya.org
SUMMARY:Esophageal Cancer CME
DESCRIPTION:[vc_row][vc_column][vc_column_text]Esophageal Cancer CME – Experience from a Regional Cancer Centre \nModerator: Dr Tracy Irura \nSpeakers & Topics: \n\nDr Omar Abdihamid: Evolving Landscape of Esophageal Cancer Treatment\nDr Abdullahi Hadi: Optimising Diagnosis of Esophageal Cancer\nDr Mohamed Noor: Surgical Approaches to Esophageal Cancer\n\nDr. Noor Mohamed provided a historical evolution of esophageal cancer surgery from Czerny’s resection to modern minimally invasive techniques.\n– Surgical resection remains critical\, especially for early-stage and select advanced cases after neoadjuvant therapy.\n– Key considerations include thorough staging (OGD\, PET-CT\, EUS)\, patient optimization (nutrition\, glycemic control)\, and perioperative care.\n– Outcomes from global surgical databases: R0 resection rates up to 93%\, 30- and 90-day mortality rates at 2% and 4.5% respectively.\n– Challenges in Kenya include late presentation\, limited access to ICU care\, and lack of trained personnel.\n– Trials such as CROSS\, PreSANO\, and SANO are shaping modern surveillance versus resection decisions in select cases. \nDr. Omar Abdihamid – emphasized that most patients in Kenya present with locally advanced disease; male/female incidence is similar.\n– Immunotherapy has shifted paradigms: CheckMate 648 showed improved OS with nivolumab + chemotherapy or ipilimumab.\n– CROSS and ESOPEC trials guide perioperative regimens (carbo/taxol RT → surgery → nivolumab vs FLOT-based therapy).\n– Early-stage SCC may be treated with endoscopic resection if well-differentiated\, superficial\, and no lymphovascular invasion.\n– Radiotherapy regimens tailored by location: cervical tumors dose-escalated up to 60Gy; others typically 50.4Gy.\n– Garissa Cancer Centre approach includes advanced IMRT planning\, with regional data contributing to genomic and QoL research.\n– SANO trial supports non-inferiority of active surveillance post-chemoradiotherapy\, showing similar OS to surgery and better QoL.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/esophageal-cancer-cme/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME),Symposia and Workshops
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250407-WA0000-e1746480214833.jpg
END:VEVENT
END:VCALENDAR